Search results
Showing 1 to 10 of 10 results for bimekizumab
Evidence-based recommendations on bimekizumab (Bimzelx) for treating axial spondyloarthritis in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
In development [GID-TA11045] Expected publication date: 20 November 2024
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
Awaiting development [GID-TA11150] Expected publication date: TBC
Discontinued [GID-TA11171]
Find out more about NICE's new proportionate approach to technology appraisals
Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]
Discontinued [GID-TA11151]
NICE approves first treatment in pilot of new approach to cost-comparison fast track appraisals
As part of the recovery from the COVID-19 pandemic, NICE has been working hard to find new ways to develop and publish guidance affected by the work programme pause in 2020, while also delivering the planned programme for 2021.